Added to YB: 2026-06-24
Pitch date: 2026-06-21
ABVX [neutral]
ABIVAX Société Anonyme
+28.44%
current return
Author Info
Alpha Talon Investment Research is a Hong Kong–based private family office deploying only proprietary capital across biotech, value turnarounds, and catalyst-driven shorts, focused on intrinsic value, regulatory odds, and mispriced fundamentals. Sign up for the newsletter.
Company Info
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Market Cap
EUR 10.3B
Pitch Price
EUR 85.80
Price Target
N/A
Dividend
N/A
EV/EBITDA
-38.82
P/E
-26.35
EV/Sales
2.0K
Sector
Biotechnology
Category
special_situation
ABIVAX (ABVX): Thesis Stress-Test After the Drawdown — Efficacy Still Shines, but Safety Optics Now Drive the Multiple
ABVX (update): UC biotech re-centered on safety after ~45% drawdown. Obefazimod Ph3 ABTECT maintenance Wk44 remission 50.8%/51.3% (25/50mg) vs 10.4% placebo (p<0.0001)—efficacy strong. Selloff on malignancy optics (mostly 50mg arm). €491.6M cash, runway into Q4 2027, FY25 burn €161M. Multiple now hinges on FDA labeling/dose selection vs takeout optionality.
Read full article (4 min)